- $1.57bn
- $2.45bn
- $1.31bn
- 96
- 71
- 68
- 93
Annual cashflow statement for Conmed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 9.52 | 62.5 | -80.6 | 64.5 | 132 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 26.5 | 31.2 | 141 | 27.9 | -9.79 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -29.9 | -55.7 | -90.7 | -39.6 | -39.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 64.5 | 112 | 33.4 | 125 | 167 |
| Capital Expenditures | -13 | -14.9 | -21.8 | -19 | -13.1 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.625 | — | -228 | -1 | 0 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -13.6 | -14.9 | -250 | -20 | -13.1 |
| Financing Cash Flow Items | -2.99 | 2.95 | -116 | 2.07 | -54.3 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -52.1 | -102 | 225 | -110 | -151 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.5 | -6.51 | 8.1 | -4.65 | 0.163 |